Liora Ter Horst

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Vlaar, A. P. J., de Bruin, S., Busch, M., Timmermans, S. A. M. E. G., van Zeggeren, I. E., Koning, R., Ter Horst, L., Bulle, E. B., van Baarle, F. E. H. P., van de Poll, M. C. G., Kemper, E. M., van der Horst, I. C. C., Schultz, M. J., Horn, J., Paulus, F., Bos, L. D., Wiersinga, W. J., Witzenrath, M., Rueckinger, S., Pilz, K. & 6 others, Brouwer, M. C., Guo, R-F., Heunks, L., van Paassen, P., Riedemann, N. C. & van de Beek, D., Dec 2020, In : The Lancet Rheumatology. 2, 12, p. e764-e773

Research output: Contribution to journal › Article › Academic › peer-review